NDAINTRAVENOUS, SUBCUTANEOUSINJECTABLEPriority Review
Approved
May 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
24
Data completeness
5/8 — Partial
Priority Review
VELCADE (bortezomib) by Takeda is proteasome inhibitors [moa]. Approved for proteasome inhibitor [epc]. First approved in 2003.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELCADE (bortezomib) is a proteasome inhibitor small-molecule oncology drug approved in 2003 for multiple myeloma and mantle cell lymphoma, with expanding use in hematologic and solid malignancies. It works by blocking the proteasome, a cellular machine that degrades proteins, causing cancer cell death through accumulation of toxic proteins. The drug is administered intravenously or subcutaneously across a broad range of hematologic and solid tumor indications.
$2.0MPart D
LOE ApproachingWith LOE approaching and minimal Part D spending relative to competitors, VELCADE teams are likely consolidating and shifting focus to lifecycle extension or new formulations rather than growth initiatives.
Mechanism of Action
Proteasome Inhibitors
Pharmacologic Class:
Proteasome Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (24)
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Started May 2026
500 enrolled
Multiple Myeloma
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Started Mar 2026
60 enrolled
Amyloidosis
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Started Aug 2024
43 enrolled
Multiple Myeloma
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
Started Jun 2024
103 enrolled
Multiple Myeloma
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Started Jan 2024
795 enrolled
Multiple Myeloma
Worked on VELCADE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.